ESPR
Price:
$1.65
Market Cap:
$323.77M
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2013-06-26
Stock Exchange
NASDAQ
Ticker
ESPR
According to Esperion Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.97. This represents a change of 11.48% compared to the average of 1.77 of the last 4 quarters.
The mean historical Current Ratio of Esperion Therapeutics, Inc. over the last ten years is 9.50. The current 1.97 Current Ratio has changed 1.97% with respect to the historical average. Over the past ten years (40 quarters), ESPR's Current Ratio was at its highest in in the March 2015 quarter at 40.33. The Current Ratio was at its lowest in in the December 2023 quarter at 1.29.
Average
9.50
Median
4.08
Minimum
1.29
Maximum
38.11
Discovering the peaks and valleys of Esperion Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 96.02%
Maximum Annual Current Ratio = 38.11
Minimum Annual Increase = -64.05%
Minimum Annual Current Ratio = 1.29
Year | Current Ratio | Change |
---|---|---|
2023 | 1.29 | -51.84% |
2022 | 2.67 | -40.41% |
2021 | 4.48 | 21.97% |
2020 | 3.68 | 14.77% |
2019 | 3.20 | 44.51% |
2018 | 2.22 | -63.97% |
2017 | 6.15 | -55.09% |
2016 | 13.70 | -64.05% |
2015 | 38.11 | 96.02% |
2014 | 19.44 | 34.80% |
The current Current Ratio of Esperion Therapeutics, Inc. (ESPR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.81
5-year avg
3.07
10-year avg
9.50
Esperion Therapeutics, Inc.’s Current Ratio is less than Elanco Animal Health Incorporated (2.93), less than SIGA Technologies, Inc. (8.25), greater than Indivior PLC (0.85), less than Catalent, Inc. (2.52), less than Eagle Pharmaceuticals, Inc. (2.16), less than ANI Pharmaceuticals, Inc. (3.97), less than Phibro Animal Health Corporation (2.94), less than Deciphera Pharmaceuticals, Inc. (4.19), less than Prestige Consumer Healthcare Inc. (3.23), greater than Collegium Pharmaceutical, Inc. (1.11), less than Pacira BioSciences, Inc. (6.82), less than Intra-Cellular Therapies, Inc. (7.81), less than Alkermes plc (2.99), less than Neurocrine Biosciences, Inc. (4.19), less than Ironwood Pharmaceuticals, Inc. (3.92), less than Avadel Pharmaceuticals plc (2.82), less than Lifecore Biomedical, Inc. (2.08), less than Rockwell Medical, Inc. (2.00), less than Kamada Ltd. (4.07), greater than Agile Therapeutics, Inc. (0.55),
Company | Current Ratio | Market cap |
---|---|---|
2.93 | $7.46B | |
8.25 | $550.26M | |
0.85 | $3.01B | |
2.52 | $10.86B | |
2.16 | $55.19M | |
3.97 | $1.27B | |
2.94 | $788.20M | |
4.19 | $2.21B | |
3.23 | $3.68B | |
1.11 | $1.20B | |
6.82 | $638.86M | |
7.81 | $7.77B | |
2.99 | $4.42B | |
4.19 | $12.13B | |
3.92 | $720.42M | |
2.82 | $1.39B | |
2.08 | $147.38M | |
2.00 | $92.47M | |
4.07 | $307.52M | |
0.55 | $10.43M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Esperion Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Esperion Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Esperion Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Esperion Therapeutics, Inc. (ESPR)?
What is the highest Current Ratio for Esperion Therapeutics, Inc. (ESPR)?
What is the 3-year average Current Ratio for Esperion Therapeutics, Inc. (ESPR)?
What is the 5-year average Current Ratio for Esperion Therapeutics, Inc. (ESPR)?
How does the current Current Ratio for Esperion Therapeutics, Inc. (ESPR) compare to its historical average?